Natera, Inc.
NTRA Nasdaq· Services-Medical Laboratories
Last close · Oct 27, 2026
$410.82
KIRA · Stoqly’s AI analyst, in plain words
- Natera, Inc. had $2.3B of revenue in fiscal 2025, up 35.9% on the year before. Over five years, revenue changed +42.6% a year on average.
- Its operating margin was −13.4%, down 0.3 pts: of every 100 in sales, about −13 is left after running the business.
- Natera, Inc. lost $208M in fiscal 2025.
- Free cash flow was $109M in fiscal 2025, 4.7% of revenue.
- Natera, Inc. has $996M more cash than debt.
Market cap
$58.9B
P/E
—
Revenue
$2.3B
Net income
−$208M
Free cash flow
$109M
Operating margin
−13.4%
Natera, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+35.9%
Yes. Sales grew 35.9% last year.
Does it make a profit?
−9.0%
No. It lost money last year.
Does profit turn into cash?
4.7%
Partly. 4.7% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Natera, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- Natera, Inc.
- CIK
- 0001604821
Natera, Inc. · NTRA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $625M | $820M | $1.1B | $1.7B | $2.3B |
| Revenue growth | 60.0% | 31.1% | 32.0% | 56.7% | 35.9% |
| Operating margin | −74.8% | −66.0% | −41.2% | −13.1% | −13.4% |
| Net income | −$472M | −$548M | −$435M | −$190M | −$208M |
| Net margin | −75.4% | −66.8% | −40.2% | −11.2% | −9.0% |
| Diluted EPS | −$5.21 | −$5.57 | −$3.78 | −$1.53 | −$1.52 |
| Cash | |||||
| Cash from operations | −$335M | −$432M | −$247M | $136M | $215M |
| Capital expenditure | $41.0M | $47.7M | $39.2M | $66.4M | $106M |
| Free cash flow | −$376M | −$479M | −$286M | $69.2M | $109M |
| FCF margin | −60.2% | −58.4% | −26.4% | 4.1% | 4.7% |
| Share count change | 11.8% | 8.7% | 16.9% | 8.5% | 9.6% |
| Debt and strength | |||||
| Cash and short-term investments | $914M | $898M | $879M | $968M | $1.1B |
| Debt incl. finance leases | $330M | $362M | $363M | $80.4M | $80.3M |
| Shareholders' equity | $653M | $706M | $765M | $1.2B | $1.7B |
| Current ratio | 5.0x | 3.9x | 4.1x | 4.0x | 3.4x |
| Interest coverage | −56.4x | −58.1x | −35.3x | −20.8x | −76.2x |
| Returns and quality | |||||
| Return on capital | −532.4% | −252.3% | −141.2% | −57.1% | −34.2% |
| Return on equity | −82.8% | −80.6% | −59.1% | −19.4% | −14.3% |
| Return on tangible equity | −72.2% | −77.6% | −56.8% | −16.1% | −17.4% |
| Piotroski F-score | 3 | 3 | 5 | 5 | 4 |
| Altman Z'' | −0.4 | −1.8 | −1.9 | 0.8 | 0.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$397M
12 insiders
Of sales under plans
87%
$346M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Natera, Inc. · NTRA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $410.82 a share, the company is worth $58.9B.
Source: SEC EDGAR XBRL filings (CIK 0001604821). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.